PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
Want to see TSE:MDMA full AI Analyst Report?
MDMA Stock Chart & Stats
C$0.11
-C$0.03(-8.33%)
At close: 4:00 PM EST
C$0.11
-C$0.03(-8.33%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.20
Previous CloseN/A
Volume63.47K
Average Volume (3M)208.17K
Market Cap
C$15.79M
Enterprise ValueC$15.68M
Total Cash (Recent Filing)C$564.71K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.62
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding108,887,215
10 Day Avg. Volume94,242
30 Day Avg. Volume208,173
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt gives the company durable financial flexibility to fund clinical-stage activities and capex without near-term interest burden. Over 2-6 months this reduces refinancing risk and supports continuing R&D and supply investments while revenues scale.
Equity CushionA meaningful equity base provides an absorptive buffer against operating losses and supports continuity of clinical supply operations. This capital cushion helps sustain operations and strategic development over several quarters before external capital is required.
Regulated MDMA Supply PositioningFocus on GMP-compliant MDMA supply targets a structural market: regulated clinical trials and potential prescription pathways in mental health. Being a qualified supplier is a high-barrier capability that supports long-term revenue opportunities as the psychedelic therapeutic ecosystem matures.
Bears Say
Negative Gross ProfitReversion to negative gross profit signals deteriorating unit economics and weak pricing or rising direct costs. If sustained, this undermines the ability to scale commercial supply profitably and requires cost restructuring or higher pricing to restore sustainable margins.
Persistent Negative Cash FlowConsistently negative operating and free cash flow forces reliance on external financing to sustain R&D and production. Over multiple quarters this can dilute shareholders, constrain discretionary investment, and raise execution risk for clinical supply and commercialization plans.
Ongoing Net Losses Eroding EquitySustained net losses reduce retained capital and the equity cushion that currently offsets zero debt. Continued erosion of equity limits strategic options, reduces financial resilience to unexpected costs, and may force equity raises or operational retrenchment.
PharmAla Biotech Holdings, Inc. News
MDMA FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was C$0.09 and its highest was C$0.20 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is C$15.79M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
Currently, no data Available
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 108,887,215 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:MDMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), as well as formulations of MDXX compounds. The company is headquartered in Vancouver, Canada.
Technical Analysis
COSCIENS Biopharma
―
Aptose Biosciences
―
Sirona Biochem
―
PreveCeutical Medical
―
PharmaTher Holdings Ltd
―
Options Prices
Currently, No data available
---